Development of synthetic biodegradable microparticulate vaccines: a roller coaster story

References

• Sanders LM, Kent JS, McRae GI, Vickery BH, Tice TR, Lewis DH. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(D,L-lactide-co-glycolide) microspheres. J. Pharm. Sci.73(9), 1294–1297 (1984).
   PubMed Web of Science ®Google Scholar
• Bloom BR. Vaccines for the Third World. Nature342(6246), 115–120 (1989).
   PubMedGoogle Scholar
• Gibbons A. A booster shot for children’s vaccines. Science255(5050), 1351 (1992).
   PubMedGoogle Scholar
• Aguado MT, Lambert PH. Controlled-release vaccines – biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology184(2–3), 113–125 (1992).
   PubMed Web of Science ®Google Scholar
• Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm.50(1), 129–146 (2000).
   PubMed Web of Science ®Google Scholar
• Johansen P, Estevez F, Zurbriggen R et al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine19(9–10), 1047–1054 (2000).
   PubMed Web of Science ®Google Scholar
• Boehm G, Peyre M, Sesardic D et al. On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm. Res.19(9), 1330–1336 (2002).
   PubMed Web of Science ®Google Scholar
• Peyre M, Audran R, Estevez F et al. Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J. Control Release99(3), 345–355 (2004).
   PubMed Web of Science ®Google Scholar
• Peyre M, Sesardic D, Merkle HP, Gander B, Johansen P. An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. J. Pharm. Sci.92(5), 957–966 (2003).
   PubMed Web of Science ®Google Scholar
• Men Y, Tamber H, Audran R, Gander B, Corradin G. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine15(12–13), 1405–1412 (1997).
   PubMed Web of Science ®Google Scholar
• Peter K, Men Y, Pantaleo G, Gander B, Corradin G. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine19(30), 4121–4129 (2001).
   PubMed Web of Science ®Google Scholar
• Ataman-Onal Y, Munier S, Ganee A et al. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control Release112(2), 175–185 (2006).
   PubMed Web of Science ®Google Scholar
• Johansen P, Raynaud C, Yang M, Colston MJ, Tascon RE, Lowrie DB. Anti-mycobacterial immunity induced by a single injection of M. leprae Hsp65-encoding plasmid DNA in biodegradable microparticles. Immunol. Lett.90(2–3), 81–85 (2003).
   PubMed Web of Science ®Google Scholar
• Otten G, Schaefer M, Greer C et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J. Virol.77(10), 6087–6092 (2003).
   PubMed Web of Science ®Google Scholar
• Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol.20, 709–760 (2002).
   PubMed Web of Science ®Google Scholar
• Sauter SL, Rahman A, Muralidhar G. Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. Curr. HIV Res.3(2), 157–181 (2005).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science259(5102), 1745–1749 (1993).
   PubMed Web of Science ®Google Scholar
• Hermanson G, Whitlow V, Parker S et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl Acad. Sci. USA101(37), 13601–13606 (2004).
   PubMed Web of Science ®Google Scholar
• Pai Kasturi S, Qin H, Thomson KS et al. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J. Control Release113(3), 261–270 (2006).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Ulmer JB. Microparticles for the delivery of DNA vaccines. Immunol. Rev.199, 191–200 (2004).
   PubMed Web of Science ®Google Scholar
• Wang C, Ge Q, Ting D et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mater.3(3), 190–196 (2004).
   PubMed Web of Science ®Google Scholar
• Brave A, Ljungberg K, Wahren B, Liu MA.Vaccine delivery methods using viral vectors. Mol. Pharm.4(1), 18–32 (2007).
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med.341(7), 468–475 (1999).
   PubMed Web of Science ®Google Scholar
• Martinez Gomez JM, Fischer S, Csaba N et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm. Res. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Niborski V, Li Y, Brennan F et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine24(49–50), 7204–7213 (2006).
   PubMed Web of Science ®Google Scholar
• Schöll I, Kopp T, Bohle B, Jensen-Jarolim E. Biodegradable PLGA particles for improved systemic and mucosal treatment of type I allergy. Immunol. Allergy Clin. North Am.26(2), 349–364, ix (2006).
   PubMed Web of Science ®Google Scholar
• Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit. Rev. Ther. Drug Carrier Syst.19(1), 73–98 (2002).
   PubMed Web of Science ®Google Scholar
• Crameri R, Flückiger S, Daigle I, Kündig T, Rhyner C. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy62(2), 197–206 (2007).
   PubMed Web of Science ®Google Scholar
• Kussebi F, Karamloo F, Rhyner C et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol.115(2), 323–329 (2005).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J. Allergy Clin. Immunol.85(2), 490–497 (1990).
   PubMed Web of Science ®Google Scholar
• Johansen P, Senti G, Martínez Gómez JM, Wüthrich B, Bot A, Kündig TM. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur. J. Immunol.35(12), 3591–3598 (2005).
   PubMed Web of Science ®Google Scholar